Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (191-200 of 277) with videos related to

Pageof 28
Sort By:
Autophagy|July 4, 2014
ATG4B promotes colorectal cancer growth independent of autophagic fluxPei-Feng Liu, Chung-Man Leung, Yu-Hsiang Chang, et al.
Future Oncology (London, England)|September 4, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutationsSuzanne George, Jean-Yves Blay, Ping Chi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2024
Facet-switching of rate-determining step on copper in CO<sub>2</sub>-to-ethylene electroreductionYu-Cai Zhang, Xiao-Long Zhang, Zhi-Zheng Wu, et al.
Targeted Oncology|April 29, 2026
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT StudyHow-Wen Ko, Ying-Ting Liao, Sheng-Kai Liang, et al.
Journal of the American Chemical Society|October 26, 2023
Gerhardtite as a Precursor to an Efficient CO-to-Acetate Electroreduction CatalystZhi-Zheng Wu, Xiao-Long Zhang, Peng-Peng Yang, et al.
Plos One|September 19, 2023
A randomized trial: The safety, pharmacokinetics and preliminary pharmacodynamics of ropivacaine oil delivery depot in healthy subjectsWu-Dang Lu, Dan-Ling Zhao, Mei-Xia Wang, et al.
Targeted Oncology|March 21, 2026
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT StudyHow-Wen Ko, Ying-Ting Liao, Sheng-Kai Liang, et al.
Cell Reports|October 14, 2020
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Cell Reports|March 1, 2018
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Nature Genetics|April 19, 2016
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanomaAmanda R Moore, Emilie Ceraudo, Jessica J Sher, et al.
Pageof 28

Showing results (191-200 of 277) with videos related to

Sort By:
Pageof 28
Autophagy|July 4, 2014
ATG4B promotes colorectal cancer growth independent of autophagic fluxPei-Feng Liu, Chung-Man Leung, Yu-Hsiang Chang, et al.
Future Oncology (London, England)|September 4, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutationsSuzanne George, Jean-Yves Blay, Ping Chi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2024
Facet-switching of rate-determining step on copper in CO<sub>2</sub>-to-ethylene electroreductionYu-Cai Zhang, Xiao-Long Zhang, Zhi-Zheng Wu, et al.
Targeted Oncology|April 29, 2026
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT StudyHow-Wen Ko, Ying-Ting Liao, Sheng-Kai Liang, et al.
Journal of the American Chemical Society|October 26, 2023
Gerhardtite as a Precursor to an Efficient CO-to-Acetate Electroreduction CatalystZhi-Zheng Wu, Xiao-Long Zhang, Peng-Peng Yang, et al.
Plos One|September 19, 2023
A randomized trial: The safety, pharmacokinetics and preliminary pharmacodynamics of ropivacaine oil delivery depot in healthy subjectsWu-Dang Lu, Dan-Ling Zhao, Mei-Xia Wang, et al.
Targeted Oncology|March 21, 2026
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT StudyHow-Wen Ko, Ying-Ting Liao, Sheng-Kai Liang, et al.
Cell Reports|October 14, 2020
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Cell Reports|March 1, 2018
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Nature Genetics|April 19, 2016
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanomaAmanda R Moore, Emilie Ceraudo, Jessica J Sher, et al.
Pageof 28